GTx, Ipsen to suspend Toremifene pact
The reason behind the termination of the agreement is the impact of the cost of second Phase III clinical trial on the business prospects for their collaboration. Toremifene
Cellares and GenomeFrontier Therapeutics have announced a collaboration to assess automated manufacturing for the latter’s investigational CAR-T cell therapy, GF-CART01, on the Cell Shuttle platform.
Globe Laboratories brings to the partnership its expertise in biopharmaceutical drugs manufacturing and development, and experience in late stage drug development. National Pharmaceuticals president and CEO Elaine Affleck